Adam Johnson

Adam Johnson

Adam Johnson is founder and author of Bullseye Brief, an investment newsletter that presents thematic and actionable ideas twice a month. He anchored several business programs at Bloomberg Television over five years, interviewing CEOs, heads of state and prominent investors. His daily video investment blog, Insight and Action, was sponsored by a major U.S. lender.

Previously he managed global risk assets for ING Furman Selz and Louis Dreyfus, trading oil futures, listed equities and equity options.

Adam began his career at Merrill Lynch with a degree in economics from Princeton.

Follow him on Twitter at @AJInsight.

Recent Articles

Best Stocks for 2017: Zynerba Pharmaceuticals Inc (ZYNE) Stock Dominates in Q1

Zynerba is working to bring its marijuana-based medications through trials and investors seem to be rewarding ZYNE stock.

3 Cheap Lithium Stocks to Buy That Will Energize Your Portfolio

Lithium is unquestionably a game changer, and these three Lithium stocks are a good way to join the party for cheap.

Alphabet Inc (GOOGL): The Cheapest $800 Stock I Know

Alphabet (GOOGL) is the most explosive innovator in global technology. Yet somehow, GOOGL stock still boasts an attractive price. Don't wait.

Best Stocks for 2017: Zynerba Pharmaceuticals Inc (ZYNE) Is a Perfect Prescription

ZYNE stock has a couple of promising therapies in trials that could make 2017 a great year for Zynerba stockholders.

Verizon Communications Inc. (VZ) Shouldn’t Even BLINK on Yahoo Deal

The Yahoo hack is unsettling, but Verizon stock is better off with YHOO under the fold regardless. It just needs to save a little face.